CD33 and leukemia: For example, erythrocyte-derived EVs effectively delivered anti-miR-214 oligonucleotides to suppress pathological bone resorption (62), and CD33-targeted EVs carrying miR-125b antisense oligonucleotides enhanced leukemia stem cell clearance (63).